CN101528308A - 治疗癌症的方法和组合物 - Google Patents

治疗癌症的方法和组合物 Download PDF

Info

Publication number
CN101528308A
CN101528308A CNA2007800385835A CN200780038583A CN101528308A CN 101528308 A CN101528308 A CN 101528308A CN A2007800385835 A CNA2007800385835 A CN A2007800385835A CN 200780038583 A CN200780038583 A CN 200780038583A CN 101528308 A CN101528308 A CN 101528308A
Authority
CN
China
Prior art keywords
day
hydroxylase
effective amount
therapeutically effective
lyase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800385835A
Other languages
English (en)
Chinese (zh)
Inventor
艾伦·H·奥尔巴克
阿里·S·贝尔德格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Oncology Inc
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101528308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of CN101528308A publication Critical patent/CN101528308A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2007800385835A 2006-08-25 2007-08-23 治疗癌症的方法和组合物 Pending CN101528308A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
US60/921,506 2006-08-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410261671.3A Division CN104306977A (zh) 2006-08-25 2007-08-23 治疗癌症的方法和组合物

Publications (1)

Publication Number Publication Date
CN101528308A true CN101528308A (zh) 2009-09-09

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800385835A Pending CN101528308A (zh) 2006-08-25 2007-08-23 治疗癌症的方法和组合物
CN201410261671.3A Pending CN104306977A (zh) 2006-08-25 2007-08-23 治疗癌症的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410261671.3A Pending CN104306977A (zh) 2006-08-25 2007-08-23 治疗癌症的方法和组合物

Country Status (20)

Country Link
EP (3) EP2061561B1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20180003636A (enExample)
CN (2) CN101528308A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2478907T3 (enExample)
ES (2) ES2869343T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2478907T3 (enExample)
PT (2) PT2478907T (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2478907T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102336801A (zh) * 2011-10-31 2012-02-01 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
CN102558274A (zh) * 2010-12-08 2012-07-11 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
CN103070828A (zh) * 2011-10-26 2013-05-01 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
WO2014075583A1 (zh) * 2012-11-13 2014-05-22 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
CN110123812A (zh) * 2013-01-15 2019-08-16 阿拉贡药品公司 雄激素受体调节剂及其用途
CN110604721A (zh) * 2013-03-15 2019-12-24 太阳药业环球公司 乙酸阿比特龙酯制剂
CN110753545A (zh) * 2017-04-13 2020-02-04 詹森药业有限公司 用于前列腺癌的联合疗法
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
US11491149B2 (en) 2017-10-16 2022-11-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
USRE49353E1 (en) 2012-09-26 2023-01-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
US11986470B2 (en) 2016-07-29 2024-05-21 Janssen Pharmaceutica Nv Methods of treating prostate cancer

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62034B1 (sr) 2006-08-25 2021-07-30 Janssen Oncology Inc Kompozicije za lečenje raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
RU2481107C2 (ru) * 2007-10-29 2013-05-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения рака
MX356704B (es) 2011-01-11 2018-06-11 Novartis Ag Combinación.
CA2831922C (en) 2011-04-01 2019-12-31 Genentech, Inc. Combinations of akt inhibitor compounds and vemurafenib, and methods of use
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2013184621A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
AU2014248001A1 (en) * 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US20160235714A1 (en) * 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
DK3935068T3 (da) * 2019-03-06 2023-12-04 Propella Therapeutics Inc Abirateron-prodrugs
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
ES2300323T3 (es) * 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
CN100528167C (zh) * 2002-10-23 2009-08-19 潘塔希生物科学股份有限公司 用于治疗癌症的包含雌四醇衍生物的药物组合物
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
RS62034B1 (sr) 2006-08-25 2021-07-30 Janssen Oncology Inc Kompozicije za lečenje raka

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558274A (zh) * 2010-12-08 2012-07-11 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
CN103070828A (zh) * 2011-10-26 2013-05-01 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801A (zh) * 2011-10-31 2012-02-01 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
USRE50642E1 (en) 2012-09-26 2025-10-21 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
USRE49353E1 (en) 2012-09-26 2023-01-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014075583A1 (zh) * 2012-11-13 2014-05-22 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
CN110123812A (zh) * 2013-01-15 2019-08-16 阿拉贡药品公司 雄激素受体调节剂及其用途
CN110123818A (zh) * 2013-01-15 2019-08-16 阿拉贡药品公司 雄激素受体调节剂及其用途
CN110604721A (zh) * 2013-03-15 2019-12-24 太阳药业环球公司 乙酸阿比特龙酯制剂
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
US11986470B2 (en) 2016-07-29 2024-05-21 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US11986468B2 (en) 2016-07-29 2024-05-21 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US11986469B2 (en) 2016-07-29 2024-05-21 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US11992486B2 (en) 2016-07-29 2024-05-28 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US12383543B2 (en) 2016-07-29 2025-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer
CN110753545A (zh) * 2017-04-13 2020-02-04 詹森药业有限公司 用于前列腺癌的联合疗法
US11491149B2 (en) 2017-10-16 2022-11-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法

Also Published As

Publication number Publication date
JP2017052791A (ja) 2017-03-16
ES2869343T3 (es) 2021-10-25
HRP20210670T1 (hr) 2021-06-11
SI2061561T1 (sl) 2013-11-29
CN104306977A (zh) 2015-01-28
EP3804730A1 (en) 2021-04-14
EP2061561A1 (en) 2009-05-27
AU2017201764A1 (en) 2017-04-06
JP2010501575A (ja) 2010-01-21
JP2020114851A (ja) 2020-07-30
AU2015221447B9 (en) 2017-07-20
JP6740497B2 (ja) 2020-08-12
HK1131577A1 (en) 2010-01-29
CY1124221T1 (el) 2022-05-27
AU2022206696A1 (en) 2022-08-11
KR20150108946A (ko) 2015-09-30
AU2015221447B2 (en) 2016-12-15
KR20090059126A (ko) 2009-06-10
KR20200125776A (ko) 2020-11-04
JP2021038252A (ja) 2021-03-11
EP2478907A2 (en) 2012-07-25
NO20200775A1 (no) 2009-03-20
SI2478907T1 (sl) 2021-08-31
CA2661422A1 (en) 2008-02-28
JP2012082215A (ja) 2012-04-26
PL2061561T3 (pl) 2013-12-31
AU2018271331A1 (en) 2018-12-20
PL2478907T3 (pl) 2021-10-25
IL227746A0 (en) 2013-09-30
RS62034B1 (sr) 2021-07-30
JP6445123B2 (ja) 2018-12-26
DK2478907T3 (da) 2021-05-25
AU2007287098A1 (en) 2008-02-28
JP2019059750A (ja) 2019-04-18
JP2024164147A (ja) 2024-11-26
HUE054495T2 (hu) 2021-09-28
JP2022185091A (ja) 2022-12-13
KR20180003636A (ko) 2018-01-09
ES2428634T3 (es) 2013-11-08
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
HRP20130961T1 (hr) 2013-11-22
DK2061561T3 (da) 2013-10-07
IL197211A0 (en) 2009-12-24
EP2478907B1 (en) 2021-04-14
LT2478907T (lt) 2021-06-25
EP2478907A3 (en) 2012-08-01
PT2478907T (pt) 2021-05-26
AU2007287098C1 (en) 2018-03-15
CY1115477T1 (el) 2017-01-04
AU2007287098B2 (en) 2013-08-15
JP2018065859A (ja) 2018-04-26
JP6053279B2 (ja) 2016-12-27
WO2008024484A1 (en) 2008-02-28
RS52956B (sr) 2014-02-28
NO20091190L (no) 2009-03-20
JP2015110577A (ja) 2015-06-18
NZ597830A (en) 2013-02-22
PT2061561E (pt) 2013-10-09
AU2015221447A1 (en) 2015-09-17
IL257681A (en) 2018-04-30
CA2661422C (en) 2017-06-27

Similar Documents

Publication Publication Date Title
JP6740497B2 (ja) 癌を治療するための方法及び組成物
US10702540B2 (en) Methods and compositions for treating cancer
US20110319369A1 (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
HK1173966A (en) Compositions for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090909